News

This article demonstrates the involvement of acid phosphatases in the higher efficacy of AMFA-labelled enzyme therapy. J Cell Mol Med. 2019;23:6499-6503.

Shire and NanomedSyn enter into research agreement for potential lysosomal storage disorder treatment. ShireNanoMedSyn_PressRelease    

NanoMedSyn  develops an efficient  treatment for refractory Pompe disease published by Journal of Controlled Release. J Control Release 2017, 269:15-23.

First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002/anie.201607824R2  

Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe’s disease.   EMA (EU/3/16/1726)

Lire l’article complet

  Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours Tremplin Entreprises.

http://www.rare2015.com/index.php      

  Information reliée par l’Académie des sciences